liver cancer
Conditions
Interventions
Calli Spheres DEB-TACE:Calli Spheres DEB-TACE
8 Spheres TACE:8 Spheres TACE
cTACE:cTACE
Sponsors
The Second Affiliated Hospital of Nantong University, Nantong First People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. According to the diagnosis and treatment standard of primary liver cancer (revised in 2017), the newly diagnosed patients with advanced primary liver cancer were diagnosed by us, MRI and other imaging examination methods, or combined with hepatocyte specific contrast agent and pathological biopsy results; 2. The patients were classified as hepatocellular carcinoma (HCC) and were unable or unwilling to undergo surgical resection. The ECoG score was 0-2, and the expected survival time was more than 3 months; 3. The coagulation function was good (platelet count > 45 x 10^9 /L) and prothrombin time was prolonged less than 3 s; 4. BCLC stage was B / C, liver and kidney functions were good (child Pugh A / B); serum creatinine was less than 1.5 times the upper limit of normal; 5. The patients have standardized and complete clinical data, and can meet the requirements of follow-up.
Exclusion criteria
Exclusion criteria: 1. Patients with other severe heart, lung, brain and kidney diseases had poor survival; 2. In patients with diffuse distant metastasis of primary liver cancer, such as bone, brain, lung metastasis or metastatic liver cancer such as liver metastasis of rectal cancer; 3. There were obvious arterio hepatic vein or arterio portal vein fistula and the fistula could not be embolized; 4. The left and right branches of portal vein were completely embolized by tumor thrombus. Or the main portal vein, superior vena cava and inferior vena cava had tumor thrombus and less collateral vessels; 5. In the course of treatment, they used other chemotherapy drugs except cisplatin / lobaplatin and doxorubicin, or received other treatments or drugs that could obviously prolong the survival time; 6. Pregnant women and those allergic to iodine, cisplatin / lobaplatin, doxorubicin and polyvinyl alcohol microspheres; 7. Patients with active hepatitis or severe infection are difficult to be treated simultaneously; 8. Others: including patients' family members who do not accept or refuse to sign the informed consent for surgery; those who cannot cooperate with treatment and follow-up during and after operation; or those who fail to follow-up within three months after enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AFP;MRI; | — |
Secondary
| Measure | Time frame |
|---|---|
| miR-122; | — |
Countries
China
Contacts
Public ContactWenbin Ding
The Second Affiliated Hospital of Nantong University, Nantong First People's Hospital
Outcome results
None listed